Advertisment ACS-IndiaSymposium
 
Journal of Pharmaceutical Negative Results
  Print this page Email this page Small font sizeDefault font sizeIncrease font size 
Search Article 
  
Advanced search 
 Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts  
 
ORIGINAL ARTICLE
Year : 2014  |  Volume : 5  |  Issue : 1  |  Page : 15-18

No impact of neuropathy on pharmacokinetic of lamotrigine in rat model


1 Department of Pharmaceutics, University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur, India
2 Department of Pharmacy, KVSR Siddhartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, India

Correspondence Address:
Hema Veesam
Department of Pharmacy, KVSR Siddhartha College of Pharmaceutical Sciences, Vijayawada 520 010, Andhra Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0976-9234.136779

Rights and Permissions

Purpose: The aim of the present research is to monitor any alteration in the serum concentrations of lamotrigine (LMT) in peripheral neuropathic conditions compared with normal conditions in a rat model. Materials and Methods: LMT concentrations were established at 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 h post dose by high performance liquid chromatography-ultraviolet. After per oral administration of 10 mg/kg drug, pharmacokinetic parameters were determined from plasma drug concentration. Later pharmacokinetic parameters of neuropathic pain induced rats were calculated in order to estimate the possible effect of neuropathic pain on pharmacokinetic parameters. Results: The regression coefficient determined for LMT calibration curve was 0.99 ± 0.001. The working range for LMT was 0.5 to 2.5 μg/ml Limit of Detection (LOD 0.2 μg/ml). The maximum drug concentration was found at 2 h. Conclusion: However, none of the pharmacokinetic parameter showed statistically significant alteration where the results were quite stimulating for the development of clinically useful oxcarbazepine dosage form to explore its activity on neuropathic pain.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3254    
    Printed130    
    Emailed0    
    PDF Downloaded271    
    Comments [Add]    
    Cited by others 2    

Recommend this journal